ZOLL AED 3 now available with Rapidshock Analysis

Delivers the Shortest Pause for more Continuous CPR

ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that the company’s ZOLL AED 3™* and the ZOLL AED 3™ BLS* (basic life support) automated external defibrillators now feature RapidShock™ Analysis technology, which decreases heart analysis time and pauses in chest compressions.

RapidShock Analysis can analyse a heart rhythm in 3 seconds, compared to existing devices, which take up to 12 seconds. Minimising CPR pause time for more continuous lifesaving CPR care can improve patient outcomes from sudden cardiac arrest. RapidShock Analysis is a free upgrade to existing ZOLL AED 3 owners in countries where it has regulatory approval.

Research shows that minimising time to shock after the CPR cycle ends may improve survival.1 The 2015 ERC Guidelines note, “The delay between stopping chest compressions and delivery of the shock (the pre-shock pause) must be kept to an absolute minimum; any delay will reduce the chances of the shock being successful.”2

“We’re pleased to be able to add this breakthrough technology to the ZOLL AED 3. It is critical to deliver consistent, high-quality chest compressions, and this technology dramatically reduces pauses, allowing for high-quality CPR,” said A. Ernest Whiton, President of ZOLL Resuscitation.

www.zoll.com
https://info.zoll.com/ukpsmgtq317w

1Snyder DE, et al. Crit Care Med. 2004;32(9) Supplement:S421-S424.
2ERC Guidelines for Resuscitation 2015. Resuscitation. 2015;95:20.
3Studies that support this statistic will be furnished upon request.
4Circulation. 2005; 112: IV-18-IV-34.

*The ZOLL AED 3 is not available for sale in the United States. This product is pending regulatory approval from the U.S. Food and Drug Administration. RapidShock Analysis is pending Health Canada approval in Canada.